Study to Determine Effectiveness of Dietary Monosaccharide Supplementation in Patients with Congenital Disorders of Glycosylation


About this study

The purpose of this study is to assess the safety and tolerability of oral monosaccharide (galactose and fucose) treatment in a small pilot group of congenital disorders of glycosylation patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  •  Patient is younger than 21 years old.
  • Patient has a biochemically and genetically proven congenital disorder of glycosylation.

Exclusion Criteria:

  • Patient has Aldolase B deficiency.
  • Patient has Galactosemia.
  • Patient has Hemolytic uremic syndrome.
  • Patient has severe anemia.
  • Patient has galactose intolerance.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Eva Morava-Kozicz, M.D., Ph.D.

Open for enrollment

Contact information:

Sarah Bohlen


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer